The capital will enable clinical development of MIV-711 for osteogenesis imperfecta (brittle bone disease), a new and strategically important indication for the Swedish pharma company. MIV-711 received orphan drug designation from the US FDA in November 2025, which provides seven years of market exclusivity after approval, regulatory support and reduced development costs.

“The board considers that MIV-711 for osteogenesis imperfecta has the potential to open up a market at least on par with that of Medivir’s drug candidate Fostrox in primary liver cancer,” the company stated.

Carl Bennet AB is an owner company with equity of approximately SEK 122 billion and principal ownership in listed companies including Getinge, Arjo, Elanders and Lifco. Medivir’s board believes the investment will provide the company with a financially strong, long-term owner that will strengthen its position in negotiations regarding partnerships and out-licensing.

The directed issue follows Medivir’s rights issue in December 2025, which raised approximately SEK 151 million to finance a randomized, controlled study of Fostrox. The company’s largest shareholders, Hallberg Management and Linc, support the directed issue.

The issue increases the number of outstanding shares from 451 million to 541 million, representing a dilution of approximately 16.6 percent for existing shareholders.